Advertisement
Screener

ORAGENICS, INC. (OGEN) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

2.8 / 5 stars · 68/120 Roast Me

ORAGENICS, INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

ORAGENICS, INC. (OGEN) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$3.20 million for the 6-month period ending 2017-06-30, per its 10-Q filed 2017-08-14.

Discontinued › Income Statement › Net Income

us-gaap:ProfitLoss · last filed 2017-08-14

  • 2017-06-30: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month -$3.20M.
  • 2016-06-30: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month -$2.38M.
Period endNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month
2017-06-30-$3.20M
10-Q · filed 2017-08-14
2016-06-30-$2.38M
10-Q · filed 2017-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
Nexentis Technologies Inc. (NXTS)$0.002B
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B
Petros Pharmaceuticals, Inc. (PTPI)United States$0.003B
GeoVax Labs, Inc. (GOVX)United States$0.003B-0.45
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
Genprex, Inc. (GNPX)United States$0.003B-0.02